We are live on
!
Find out more
Aberdeen Group Portfolio holdings
AUM
$61.9B
1-Year Est. Return
29.81%
This Fund
S&P 500
This Quarter
Est. Return
+5.07%
1 Year Est. Return
+29.81%
3 Year Est. Return
+93.17%
5 Year Est. Return
+119.65%
10 Year Est. Return
–
AUM
$64.6B
AUM Growth
+$1.37B
(+2.2%)
Cap. Flow
-$686M
Cap. Flow
% of AUM
-1.06%
Top 10 Holdings %
Top 10 Hldgs %
38.17%
Holding
995
New
43
Increased
362
Reduced
491
Closed
59
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Nu Holdings
NU
|
+$36.3M |
| 2 |
SCHW
Charles Schwab
SCHW
|
+$36.1M |
| 3 |
Ascendis Pharma A/S
ASND
|
+$35.6M |
| 4 |
Danaher
DHR
|
+$30.5M |
| 5 |
uniQure
QURE
|
+$28.5M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Eli Lilly
LLY
|
+$93.5M |
| 2 |
Mercado Libre
MELI
|
+$86M |
| 3 |
Microsoft
MSFT
|
+$62.9M |
| 4 |
Apple
AAPL
|
+$55.6M |
| 5 |
BioMarin Pharmaceuticals
BMRN
|
+$48.9M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 32.59% |
| 2 | Healthcare | 13.39% |
| 3 | Consumer Discretionary | 11.41% |
| 4 | Communication Services | 11.25% |
| 5 | Financials | 10.55% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
426
Equifax
EFX
$20.7B
| $20.2M | 0.03% |
92,887
-1,841
| -2% | -$403K |
|
427
Church & Dwight Co
CHD
$23.1B
| $20.1M | 0.03% |
240,062
+4,642
| +2% | +$397K |
|
428
GDS Holdings
GDS
$6.41B
| $20.1M | 0.03% |
576,498
+124,473
| +28% | +$4.3M |
|
429
NRG Energy
NRG
$28.3B
| $20.1M | 0.03% |
126,304
-3,702
| -3% | -$613K |
|
430
Meritage Homes
MTH
$4.72B
| $20.1M | 0.03% |
305,475
+44,975
| +17% | +$3.11M |
|
431
Hershey
HSY
$35.9B
| $20.1M | 0.03% |
110,341
+1,213
| +1% | +$222K |
|
|
GRMN
432
Garmin
GRMN
$57.4B
| $19.9M | 0.03% |
98,328
-7,118
| -7% | -$1.55M |
|
433
Travere Therapeutics
TVTX
$5.33B
| $19.8M | 0.03% |
518,357
-449,028
| -46% | -$14.6M |
|
434
Badger Meter
BMI
$3.78B
| $19.7M | 0.03% |
113,025
-9
| -0% | -$1.62K |
|
435
Valero Energy
VLO
$92.6B
| $19.7M | 0.03% |
120,916
-348
| -0.3% | -$59K |
|
436
NiSource
NI
$21.6B
| $19.7M | 0.03% |
471,016
+84,252
| +22% | +$3.6M |
|
437
Brinker International
EAT
$9B
| $19.6M | 0.03% |
136,564
+10,891
| +9% | +$1.43M |
|
438
DuPont de Nemours
DD
$18.7B
| $19.6M | 0.03% |
162,206
-232,478
| -59% | -$26.2M |
|
439
Fortive
FTV
$17.7B
| $19.5M | 0.03% |
353,520
+37,828
| +12% | +$1.96M |
|
440
PTC
PTC
$15.7B
| $19.4M | 0.03% |
111,416
-95
| -0.1% | -$17.7K |
|
441
IDEAYA Biosciences
IDYA
$3.5B
| $19.4M | 0.03% |
560,623
+2,575
| +0.5% | +$82.1K |
|
442
Charles River Laboratories
CRL
$11.3B
| $19.3M | 0.03% |
97,001
+88,853
| +1,090% | +$16.1M |
|
|
Q
443
Qnity Electronics Inc
Q
$27.3B
| $19.3M | 0.03% |
+236,836
| New | +$20.1M |
|
444
T. Rowe Price
TROW
$25.6B
| $19.3M | 0.03% |
188,818
-14,587
| -7% | -$1.51M |
|
445
Aptiv
APTV
$12.3B
| $19.3M | 0.03% |
253,963
-809
| -0.3% | -$64.9K |
|
446
Veeva Systems
VEEV
$32.7B
| $19.2M | 0.03% |
86,098
+4,832
| +6% | +$1.28M |
|
|
BLD
447
DELISTED
TopBuild
BLD
| $19.2M | 0.03% |
46,066
-742
| -2% | -$318K |
|
448
Atlassian
TEAM
$24.9B
| $19.1M | 0.03% |
117,775
+2,997
| +3% | +$470K |
|
449
Clearway Energy Class C
CWEN
$4.94B
| $19.1M | 0.03% |
573,647
-6,660
| -1% | -$222K |
|
450
Host Hotels & Resorts
HST
$17.2B
| $19.1M | 0.03% |
1,075,789
+6,955
| +0.7% | +$120K |
|
Similar funds
Aberdeen Group's Q4 2025 Portfolio in Review
As of Q4 2025, Aberdeen Group held 995 positions worth $64.6B, up 2.2% from $63.2B the previous quarter. Its ten largest holdings account for 38% of the portfolio.
Aberdeen Group's Q4 2025 filing shows 43 new, 362 increased, 491 reduced and 59 closed positions. Its largest new stake was Praxis Precision Medicines: 134,992 shares worth $39.8M. The largest sale was Eli Lilly, an estimated $93.5M.
By sector, the portfolio is most concentrated in Technology at 33% of assets, down from 33% a quarter earlier, followed by Healthcare and Consumer Discretionary.
- Aberdeen Group's largest Q4 2025 buy was Praxis Precision Medicines: 134,992 shares worth $39.8M.
- Aberdeen Group added most to Nu Holdings in Q4 2025, an estimated $36.3M increase.
- Aberdeen Group's biggest Q4 2025 reduction was Eli Lilly, cutting an estimated $93.5M.
- Aberdeen Group fully exited BioMarin Pharmaceuticals in Q4 2025, selling an estimated $48.9M.
- Aberdeen Group's ten largest holdings make up 38% of its $64.6B portfolio in Q4 2025.
- Aberdeen Group opened 43 new positions and closed 59 in Q4 2025.
- Aberdeen Group's portfolio value rose 2.2% quarter-over-quarter to $64.6B.
Based on Aberdeen Group's 13F filing for Q4 2025, filed 16 Jan 2026.